MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based...

EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and...

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple...

NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM This is a randomized,...

NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide...

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...

NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812: Phase 1/2 Study of ISB 1442 in...

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...

SWOG - S2209 - Southwest Oncology Group NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma...

NCT05256446: AMG 701 Expanded Access Program AMG 701 Expanded Access Program Expanded access requests for AMG 701 may be considered for...

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma Study of ORIC-533 in Relapsed or Refractory Multiple...

NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma This is a phase II study to determine the...

CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480...

(SUCCESSOR-2) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib...

MASTER-2 NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2) NCT05231629: Phase 2:...

(MajesTEC-7) Newly diagnosed Multiple Myeloma NCT05552222: Phase 3: A Study to Compare Teclistamab in Combination With Daratumumab and...

NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma NDMM RRMM The...

NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell...

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug...

NCT05338775: Phase 1: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor...

MagnetisMM-7 NCT05317416: Phase 3: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After...

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in...

EMN30 - MajesTEC-4 64007957MMY3003 NCT05243797: Phase 3: Teclistamab + Lenalidomide Versus Lenalidomide Alone in NDMM Myeloma as...

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell...

NCT05218603: Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone...

NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell...

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma FT576 in Subjects With Multiple Myeloma This is a Phase I dose-finding...

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721:...

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel NCT05201781: Phase 4: A...

NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...

NCT05354557: Phase 2 - Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant...

DREAMM 12 Relapsed & Refractory Myeloma NCT04398745: Phase 1: A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma...

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) Compassionate Use (CU) of REGN5458 for...

NCT05064358: Phase 2 - Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or...

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma This research study involves the study of TriPRIL CAR T Cells for treating...

FUMANBA-1 NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory...

Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple...

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this...

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma...

NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab NCT05053607: Real World...

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma Descartes-25 in Relapsed/Refractory Multiple Myeloma This is...

PERK Inhibitor NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma Ph I Study of...

EMN 29 NCT05028348: Phase 3: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide,...

MagnetisMM-5 Relapsed Refractory Multiple Myeloma NCT05020236: Phase 3 - MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and...